Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7544178 | 0.88 | RARB (0.47) | TDP1MAPK1KMT2ARAB9AMEN1 | |
| SCHEMBL7543027 | 0.87 | TDP1 (0.42) | TDP1MAPK1KMT2ARAB9AMEN1 | |
| SCHEMBL7543086 | 0.87 | TDP1 (0.42) | TDP1MAPK1KMT2ARAB9AMEN1 | |
| SCHEMBL2608829 | 0.81 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL11951667 | 0.80 | TDP1 (0.53) | TDP1MAPK1EPHX2KMT2ARAB9A | |
| 1,4-Diisopentoxybenzene SCHEMBL2846102 | 0.80 | TDP1 (0.79) | TDP1MAPK1EPHX2KMT2ARAB9A | |
| SCHEMBL16997128 | 0.79 | TDP1 (0.50) | TDP1MAPK1EPHX2KMT2ARAB9A | |
| SCHEMBL3335244 | 0.79 | MAPT (0.64) | KMT2ARAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL7941127 | 0.79 | MAPT (0.55) | MAPK1KMT2ARAB9AMAPTCHRNB2 | |
| SCHEMBL21156450 | 0.78 | RARB (0.51) | TDP1MAPK1EPHX2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11560376-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA (US) | 2017-05-25 | — | — | US | disclosed |
| US-9511067-B2 | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-06 | — | — | US | disclosed |
| WO-2016191172-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-25 | — | — | US | disclosed |
| US-8916565-B2 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-23 | — | — | US | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| EP-1219607-B1 | INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES | SHIONOGI & CO (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7576198-B1 | Integrase inhibitors containing aromatic heterocycle derivatives | SHIONOGI & CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| EP-1219607-A1 | INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174127-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | TDP1 3809/4885MAPK1 3165/4885EPHX2 2779/4885 |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | TDP1 3809/4885MAPK1 3165/4885EPHX2 2779/4885 |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | TDP1 4709/4885MAPK1 1617/4885EPHX2 4410/4885 |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TDP1 4837/4885MAPK1 3157/4885EPHX2 2041/4885 |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | TDP1 4657/4885MAPK1 2210/4885EPHX2 4524/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | TDP1 3809/4885MAPK1 3165/4885EPHX2 2779/4885 |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | TDP1 4709/4885MAPK1 1617/4885EPHX2 4410/4885 |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | TDP1 4657/4885MAPK1 2210/4885EPHX2 4524/4885 |
| US-11560376-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | TDP1 4709/4885MAPK1 1617/4885EPHX2 4410/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | TDP1 4550/4885MAPK1 2112/4885EPHX2 4107/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | TDP1 4651/4885MAPK1 1668/4885EPHX2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.